{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:08Z","timestamp":1740126428001,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005107","name":"Australasian Blistering Diseases Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005107","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glucocorticoid use in patients with autoimmune bullous disease is associated with significant morbidity, and in some cases, excess mortality. The hyperglycaemic complications arising from glucocorticoid use have been well-documented and range from mild hyperglycaemia to diabetic ketoacidosis. Patients with pre-existing glucose intolerance or type 2 diabetes mellitus are at increased risk of developing complications. Several other factors have been investigated for their association with steroid-induced hyperglycaemia, including patient age, sex, family history, dose, regimen and duration of therapy. Findings in the current literature, however, are largely conflicting and evidence is limited by methodological weaknesses. Glucocorticoids should be used with caution, and patients using steroids should be closely monitored for adverse effects.<\/jats:p>","DOI":"10.1093\/ced\/llac137","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:26:17Z","timestamp":1674224777000},"page":"448-452","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-2554","authenticated-orcid":false,"given":"Joslin S","family":"Johal","sequence":"first","affiliation":[{"name":"Department of Dermatology, St George Hospital , Sydney , Australia"},{"name":"Faculty of Medicine, UNSW , Sydney , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-269X","authenticated-orcid":false,"given":"Timothy L","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St George Hospital , Sydney , Australia"},{"name":"Faculty of Medicine, UNSW , Sydney , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"Dedee F","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St George Hospital , Sydney , Australia"},{"name":"Faculty of Medicine, UNSW , Sydney , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"2023100416440022600_llac137-B1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"2023100416440022600_llac137-B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-662-45698-9_2","volume-title":"Blistering Diseases","author":"Karlmark","year":"2015"},{"key":"2023100416440022600_llac137-B3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/archderm.1976.01630310024005","article-title":"A 20\u2005year review of 107 patients treated with corticosteroids","volume":"112","author":"Rosenberg","year":"1976","journal-title":"Arch Dermatol"},{"volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017","author":"National Cancer Institute","key":"2023100416440022600_llac137-B4"},{"key":"2023100416440022600_llac137-B5","doi-asserted-by":"crossref","first-page":"e0463","DOI":"10.1097\/MD.0000000000010463","article-title":"Immunological markers as predictors of developing steroid-induced diabetes mellitus in pemphigus vulgaris patients: an observational study","volume":"97","author":"D\u00e2nescu","year":"2018","journal-title":"Medicine"},{"key":"2023100416440022600_llac137-B6","first-page":"13030\/qt96v387cj","article-title":"Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients","volume":"23","author":"Brown","year":"2018","journal-title":"Dermatol Online J"},{"key":"2023100416440022600_llac137-B7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jdv.16188","article-title":"Results of the guideline-based treatment for pemphigus: a single-centre experience with 84 cases","volume":"34","author":"Kakuta","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416440022600_llac137-B8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/ijdvl.IJDVL_323_17","article-title":"Clinical, immunological profile and follow up of patients with pemphigus: a study from India","volume":"84","author":"Ramassamy","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2023100416440022600_llac137-B9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1365-4632.2012.05470.x","article-title":"Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus","volume":"51","author":"Alavi","year":"2012","journal-title":"Int J Dermatol"},{"key":"2023100416440022600_llac137-B10","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaad.2019.11.018","article-title":"Diabetes mellitus and hyperglycemic complications in bullous pemphigoid","volume":"82","author":"Chai","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023100416440022600_llac137-B11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1346-8138.2003.tb00464.x","article-title":"Immediate and delayed complications of dexamethasone cyclophosphamide pulse (DCP) therapy","volume":"30","author":"Jain","year":"2003","journal-title":"J Dermatol"},{"key":"2023100416440022600_llac137-B12","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1365-4632.2010.04698.x","article-title":"Longterm clinical remission of oral and cutaneous pemphigus with thalidomide","volume":"50","author":"Lee","year":"2011","journal-title":"Int J Dermatol"},{"key":"2023100416440022600_llac137-B13","doi-asserted-by":"crossref","first-page":"13030\/qt1vk2m30m","DOI":"10.5070\/D32312037664","article-title":"Association of pemphigus and systemic corticosteroid use with comorbid health disorders: a case-control study","volume":"23","author":"Hsu","year":"2017","journal-title":"Dermatol Online J"},{"key":"2023100416440022600_llac137-B14","doi-asserted-by":"crossref","first-page":"e1\u2013e3","DOI":"10.1111\/ijd.15238","article-title":"Pemphigus and diabetes mellitus: a systematic review and meta-analysis","volume":"60","author":"Phan","year":"2021","journal-title":"Int J Dermatol"},{"key":"2023100416440022600_llac137-B15","first-page":"375","article-title":"Assessment of the prevalence and risk factors associated with glucocorticoid-induced diabetes mellitus in pemphigus vulgaris patients","volume":"55","author":"Darjani","year":"2017","journal-title":"Acta Med Iran"},{"key":"2023100416440022600_llac137-B16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1590\/abd1806-4841.20142930","article-title":"Prevalence of metabolic syndrome and its components in a Brazilian sample of pemphigus patients","volume":"89","author":"Ambiel","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2023100416440022600_llac137-B17","first-page":"301","article-title":"Risk factors and frequency of steroid-induced diabetes in pemphigus vulgaris patients during 1\u2005year study","volume":"6","author":"Valikhani","year":"2007","journal-title":"Iranian J Diabetes Lipid Disord"},{"key":"2023100416440022600_llac137-B18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100416440022600_llac137-B19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1365-4362.1995.tb04430.x","article-title":"Dexamethasone-cyclophosphamide pulse therapy for pemphigus","volume":"34","author":"Pasricha","year":"1995","journal-title":"Int J Dermatol"},{"key":"2023100416440022600_llac137-B20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2133.2009.09590.x","article-title":"Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus","volume":"162","author":"Saha","year":"2010","journal-title":"Br J Dermatol"},{"key":"2023100416440022600_llac137-B21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"2023100416440022600_llac137-B22","first-page":"334","article-title":"Treatment of pemphigus with intravenous pulse cyclophosphamide","volume":"69","author":"Gokhale","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2023100416440022600_llac137-B23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-4632.2005.02218.x","article-title":"Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int J Dermatol"},{"key":"2023100416440022600_llac137-B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1468-3083.2002.00461.x","article-title":"Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols","volume":"16","author":"Femiano","year":"2002","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"2023100416440022600_llac137-B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2133.1988.tb07104.x","article-title":"Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus","volume":"119","author":"Pasricha","year":"1988","journal-title":"Br J Dermatol"},{"key":"2023100416440022600_llac137-B26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","article-title":"Glucocorticoids and the risk for initiation of hypoglycemic therapy","volume":"154","author":"Gurwitz","year":"1994","journal-title":"Arch Intern Med"},{"key":"2023100416440022600_llac137-B27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023100416440022600_llac137-B28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"key":"2023100416440022600_llac137-B29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023100416440022600_llac137-B30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdin.2021.09.003","article-title":"Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: a cohort study","volume":"6","author":"Liang","year":"2022","journal-title":"JAAD Int"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llac137\/49166428\/llac137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/5\/448\/51854716\/llac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/5\/448\/51854716\/llac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T16:44:25Z","timestamp":1696437865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/5\/448\/6966545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,1]]},"published-print":{"date-parts":[[2023,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llac137","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,1,1]]}}}